Maravai LifeSciences Holdings, Inc. (MRVI)

Market Cap	1.17B
Revenue (ttm)	276.92M
Net Income (ttm)	-224.66M
Shares Out	252.53M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,978
Open	4.740
Previous Close	4.630
Day's Range	4.630 - 4.740
52-Week Range	4.275 - 11.560
Beta	0.02
Analysts	Buy
Price Target	10.33 (+123.11%)
Earnings Date	Nov 7, 2024

About MRVI

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in tw...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 20, 2020
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: MRVI
• Website: https://www.maravai.com

Analyst Forecast

According to 11 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price forecast is $10.33, which is an increase of 123.11% from the latest price.

Price Target

$10.33

(123.11% upside)

Analyst Consensus: Buy